Takeda Pharmaceutical Company Limited
CANNABINOID RECEPTOR TYPE 1 (CB1) BINDING PROTEINS AND USES THEREOF
Last updated:
Abstract:
The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
Status:
Application
Type:
Utility
Filling date:
16 Mar 2021
Issue date:
1 Jul 2021